Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

MCLEAN, Va., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (TLI), a not-for-profit organization that works at the nexus of science, ...

Our eyesight is essential to getting around, but if you’re not careful it can be seriously challenged by age-related macular ...

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with diabetic macular edema with ...

Macular degeneration is very common and affects an estimated 19.8 million people in the United States. Approximately one in 10 Americans age 50 and older have an early form of the disease and as many ...

Breakthroughs in age-related macular degeneration (AMD) treatments have revolutionized the management of this progressive and potentially devastating eye disease. These include treatments such as ...

According to the Centers for Disease Control and Prevention, in 2019 an estimated 19.8 million Americans 40 years and older were living with age-related macular degeneration. “It’s more likely ...

Macular degeneration usually refers to the age-related degenerative changes in the retina that can result in loss of central vision. It is caused by abnormal blood vessel growth (a condition ...

Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...

“I am excited to offer Susvimo to my patients living with diabetic macular edema who want an option with longer ... “Having completed dozens of Susvimo surgeries in my patients with wet, or ...